Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907)

Tomoya Yokota; Nobutoshi Ando; Hiroyasu Igaki; Masayuki Shinoda; Ken Kato; Junki Mizusawa; Hiroshi Katayama; Kenichi Nakamura; Haruhiko Fukuda; Yuukou Kitagawa

doi:10.1159/000381065

Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907)

Tomoya Yokota, Nobutoshi Ando, Hiroyasu Igaki, Masayuki Shinoda, Ken Kato, Junki Mizusawa, Hiroshi Katayama, Kenichi Nakamura, Haruhiko Fukuda, Yuukou Kitagawa

外科学(一般・消化器)

研究成果: Article

21 引用（Scopus）

抜粋

Objective: Neoadjuvant chemotherapy with 5-fluorouracil plus cisplatin and subsequent esophagectomy with two- to three-field lymphadenectomy is a standard treatment for patients with clinical stage II/III squamous cell carcinoma (SCC) of the esophagus. This study investigates the prognostic factors for patients who received neoadjuvant chemotherapy. Methods: Of 164 patients assigned to receive neoadjuvant chemotherapy in the JCOG9907 trial, multivariate analyses were performed for 159 and 149 patients to evaluate the preoperative and the combined preoperative and postoperative prognostic factors, respectively. Results: The multivariate analyses using preoperative factors showed that clinical stage T3 [vs. cT1-2; hazard ratio (HR) 3.60, p = 0.0007] and serum albumin (Alb)

元の言語	English
ページ（範囲）	143-151
ページ数	9
ジャーナル	Oncology (Switzerland)
巻	89
発行部数	3
DOI	https://doi.org/10.1159/000381065
出版物ステータス	Published - 2015 8 21

フィンガープリント

ASJC Scopus subject areas

Cancer Research
Oncology

これを引用

Yokota, T., Ando, N., Igaki, H., Shinoda, M., Kato, K., Mizusawa, J., Katayama, H., Nakamura, K., Fukuda, H., & Kitagawa, Y. (2015). Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907). Oncology (Switzerland), 89(3), 143-151. https://doi.org/10.1159/000381065

Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907). / Yokota, Tomoya; Ando, Nobutoshi; Igaki, Hiroyasu; Shinoda, Masayuki; Kato, Ken; Mizusawa, Junki; Katayama, Hiroshi; Nakamura, Kenichi; Fukuda, Haruhiko; Kitagawa, Yuukou.

：: Oncology (Switzerland), 巻 89, 番号 3, 21.08.2015, p. 143-151.

研究成果: Article

Yokota, Tomoya ; Ando, Nobutoshi ; Igaki, Hiroyasu ; Shinoda, Masayuki ; Kato, Ken ; Mizusawa, Junki ; Katayama, Hiroshi ; Nakamura, Kenichi ; Fukuda, Haruhiko ; Kitagawa, Yuukou. / Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907). ：: Oncology (Switzerland). 2015 ; 巻 89, 番号 3. pp. 143-151.

@article{0c8c939da86b45c1a6b5a6644cc62ab4,

title = "Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907)",

abstract = "Objective: Neoadjuvant chemotherapy with 5-fluorouracil plus cisplatin and subsequent esophagectomy with two- to three-field lymphadenectomy is a standard treatment for patients with clinical stage II/III squamous cell carcinoma (SCC) of the esophagus. This study investigates the prognostic factors for patients who received neoadjuvant chemotherapy. Methods: Of 164 patients assigned to receive neoadjuvant chemotherapy in the JCOG9907 trial, multivariate analyses were performed for 159 and 149 patients to evaluate the preoperative and the combined preoperative and postoperative prognostic factors, respectively. Results: The multivariate analyses using preoperative factors showed that clinical stage T3 [vs. cT1-2; hazard ratio (HR) 3.60, p = 0.0007] and serum albumin (Alb) ",

keywords = "Clinical T stage, Esophageal squamous cell carcinoma, Neoadjuvant chemotherapy, Pathological findings, Prognostic factors, Serum albumin",

author = "Tomoya Yokota and Nobutoshi Ando and Hiroyasu Igaki and Masayuki Shinoda and Ken Kato and Junki Mizusawa and Hiroshi Katayama and Kenichi Nakamura and Haruhiko Fukuda and Yuukou Kitagawa",

year = "2015",

month = aug

day = "21",

doi = "10.1159/000381065",

language = "English",

volume = "89",

pages = "143--151",

journal = "Oncology (Switzerland)",

issn = "0030-2414",

publisher = "S. Karger AG",

number = "3",

}

TY - JOUR

T1 - Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907)

AU - Yokota, Tomoya

AU - Ando, Nobutoshi

AU - Igaki, Hiroyasu

AU - Shinoda, Masayuki

AU - Kato, Ken

AU - Mizusawa, Junki

AU - Katayama, Hiroshi

AU - Nakamura, Kenichi

AU - Fukuda, Haruhiko

AU - Kitagawa, Yuukou

PY - 2015/8/21

Y1 - 2015/8/21

N2 - Objective: Neoadjuvant chemotherapy with 5-fluorouracil plus cisplatin and subsequent esophagectomy with two- to three-field lymphadenectomy is a standard treatment for patients with clinical stage II/III squamous cell carcinoma (SCC) of the esophagus. This study investigates the prognostic factors for patients who received neoadjuvant chemotherapy. Methods: Of 164 patients assigned to receive neoadjuvant chemotherapy in the JCOG9907 trial, multivariate analyses were performed for 159 and 149 patients to evaluate the preoperative and the combined preoperative and postoperative prognostic factors, respectively. Results: The multivariate analyses using preoperative factors showed that clinical stage T3 [vs. cT1-2; hazard ratio (HR) 3.60, p = 0.0007] and serum albumin (Alb)

AB - Objective: Neoadjuvant chemotherapy with 5-fluorouracil plus cisplatin and subsequent esophagectomy with two- to three-field lymphadenectomy is a standard treatment for patients with clinical stage II/III squamous cell carcinoma (SCC) of the esophagus. This study investigates the prognostic factors for patients who received neoadjuvant chemotherapy. Methods: Of 164 patients assigned to receive neoadjuvant chemotherapy in the JCOG9907 trial, multivariate analyses were performed for 159 and 149 patients to evaluate the preoperative and the combined preoperative and postoperative prognostic factors, respectively. Results: The multivariate analyses using preoperative factors showed that clinical stage T3 [vs. cT1-2; hazard ratio (HR) 3.60, p = 0.0007] and serum albumin (Alb)

KW - Clinical T stage

KW - Esophageal squamous cell carcinoma

KW - Neoadjuvant chemotherapy

KW - Pathological findings

KW - Prognostic factors

KW - Serum albumin

UR - http://www.scopus.com/inward/record.url?scp=84942196741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942196741&partnerID=8YFLogxK

U2 - 10.1159/000381065

DO - 10.1159/000381065

M3 - Article

C2 - 25895447

AN - SCOPUS:84942196741

VL - 89

SP - 143

EP - 151

JO - Oncology (Switzerland)

JF - Oncology (Switzerland)

SN - 0030-2414

IS - 3

ER -

文献にアクセス

10.1159/000381065